Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling 911,128 shares, a decline of 12.7% from the February 12th total of 1,043,199 shares. Based on an average daily volume of 511,599 shares, the short-interest ratio is presently 1.8 days. Currently, 4.0% of the shares of the stock are sold short. Currently, 4.0% of the shares of the stock are sold short. Based on an average daily volume of 511,599 shares, the short-interest ratio is presently 1.8 days.

Institutional Trading of Medicus Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Medicus Pharma in the 2nd quarter worth $41,000. HRT Financial LP bought a new stake in Medicus Pharma during the fourth quarter worth about $42,000. Osaic Holdings Inc. increased its holdings in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Medicus Pharma by 161.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after buying an additional 17,611 shares during the last quarter. Finally, Brave Asset Management Inc. bought a new stake in shares of Medicus Pharma during the third quarter valued at approximately $46,000.

Analyst Ratings Changes

MDCX has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $27.00 price objective on shares of Medicus Pharma in a research note on Monday, March 9th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX stock traded down $0.01 during trading on Tuesday, hitting $0.52. 844,104 shares of the company were exchanged, compared to its average volume of 4,335,703. The business’s 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.80. Medicus Pharma has a twelve month low of $0.37 and a twelve month high of $8.94. The firm has a market capitalization of $13.18 million, a price-to-earnings ratio of -0.24 and a beta of -1.60.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.